Ms. Shaw, who assumed her role in 2017, will be replaced by the drugmaker’s top executive in Japan, Patrik Jonsson.
The chief of biomedicines role is critical because many of Eli Lilly’s main growth drivers fall under the biomedicine category, including its cancer and migraine prevention drugs.
Eli Lilly also announced its general counsel, Mike Harrington, will retire at the end of the year. The drugmaker is searching for his successor.
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
